Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066

Moleculin Biotech, Inc. recently announced enrollment has opened for a physician-sponsored clinical trial of WP1066 for the treatment of glioblastoma and brain metastases in adults.

“We have been eagerly awaiting the beginning of this physician-sponsored clinical trial,”saidd Walter Klemp, Chairman and CEO of Moleculin. “The trial, which is now listed on and being conducted at MD Anderson Cancer Center, is now open for enrollment. This is our first investigator initiated trial of WP1066 and an important milestone. Given the unique potential of WP1066, we expect more trials to follow.”

The goal of this clinical research study is to find the highest tolerable dose of WP1066 that can be given to patients with recurrent (has returned after treatment) cancerous brain tumors or melanoma that has spread to the brain. The safety of this drug will also be studied.

WP1066 is designed to target the STAT3 pathway in cancer cells, which makes these cells divide, increases new blood vessels to the tumor, causes the cancer cells to move throughout the body and brain, and avoids them being detected by the immune system. We believe that targeting this pathway may cause the immune system to kill the cancer cells.

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors. For more information about the Company, please visit